OCUL logo

Ocular Therapeutix (OCUL) EBITDA

Annual EBITDA

-$66.42 M
-$4.51 M-7.28%

December 31, 2023

Summary

Performance

1-Year Change

-7.28%

3-Year Change

+54.54%

5-Year Change

-18.7%

15-Year Change

-10.93%

OCUL EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

26.87%
OCUL annual EBITDA is higher than 26.87% of companies in Healthcare sector

High & Low

All-time High

$2.54 M
OCUL annual EBITDA is currently -2715.79% below its historical high of $2.54 million

3-Year Low

-$66.42 M
OCUL annual EBITDA is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
OCUL previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 11, 2025
OCUL next annual earnings announcement is scheduled for Mar 11, 2025

OtherOCULprofitabilitymetrics:

Annual Revenue

$58.44 M
OCUL annual revenue is $58.44 million

Annual Net Income

-$80.74 M
OCUL annual net profit is -$80.74 million

Annual EBIT

-$69.40 M
OCUL annual earnings before interest & taxes is -$69.40 million

Annual EPS

-$1.02
OCUL annual earnings per share is -$1.02

Quarterly EBITDA

-$32.31 M
+$7.32 M+18.46%

September 30, 2024

Summary

Performance

3-Month Change

+18.46%

1-Year Change

-950.26%

3-Year Change

-758.18%

5-Year Change

-92.46%

OCUL Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

14.58%
OCUL quarterly EBITDA is higher than 14.58% of companies in Healthcare sector

High & Low

All-time High

$5.45 M
OCUL quarterly EBITDA is currently -693.28% below its historical high of $5.45 million

3-Year Low

-$59.88 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
OCUL previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 11, 2025
OCUL next earnings announcement is scheduled for Mar 11, 2025

OtherOCULprofitabilitymetrics:

Quarterly Revenue

$15.43 M
OCUL quarterly revenue is $15.43 million

Quarterly Net Income

-$36.49 M
OCUL quarterly net profit is -$36.49 million

Quarterly EBIT

-$33.27 M
OCUL quarterly earnings before interest & taxes is -$33.27 million

Quarterly EPS

-$0.22
OCUL quarterly earnings per share is -$0.22

TTM EBITDA

-$155.92 M
-$36.11 M-30.14%

September 30, 2024

Summary

Performance

3-Month Change

-30.14%

1-Year Change

-180.89%

3-Year Change

-97.17%

5-Year Change

-100.57%

OCUL TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

11.36%
OCUL TTM EBITDA is higher than 11.36% of companies in Healthcare sector

High & Low

All-time High

$2.54 M
OCUL TTM EBITDA is currently -6238.70% below its historical high of $2.54 million

3-Year Low

-$155.92 M
OCUL TTM EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
OCUL previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 11, 2025
OCUL next earnings announcement is scheduled for Mar 11, 2025

OtherOCULprofitabilitymetrics:

TTM Revenue

$61.44 M
OCUL TTM revenue is $61.44 million

TTM Net Income

-$174.34 M
OCUL TTM net profit is -$174.34 million

TTM EBIT

-$159.72 M
OCUL TTM earnings before interest & taxes is -$159.72 million

TTM EPS

-$1.32
OCUL TTM earnings per share is -$1.32

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$66.42 M
OCUL annual EBITDA is -$66.42 million

Annual Net Income

-$80.74 M
OCUL annual net profit is -$80.74 million

Annual Interest Expense

$11.34 M
OCUL annual interest expense is $11.34 million

Annual Income Tax

-
OCUL annual income tax value is unknown

Annual D&A

$2.98 M
OCUL annual depreciation & amortization is $2.98 million

OCUL EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-7.3%-950.3%-180.9%
3 y3 years+54.5%-758.2%-97.2%
5 y5 years-18.7%-92.5%-100.6%

OCUL EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-2715.8%at low-950.3%+46.0%-6238.7%at low
5 y5-year-2715.8%+54.5%-693.3%+61.2%-6238.7%at low
alltimeall time-2715.8%+54.5%-693.3%+61.2%-6238.7%at low

Ocular Therapeutix EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$32.31 M(-18.5%)
-$155.92 M(+30.1%)
Jun 2024
-
-$39.63 M(-33.8%)
-$119.81 M(+22.0%)
Mar 2024
-
-$59.88 M(+148.3%)
-$98.23 M(+47.9%)
Dec 2023
-$66.42 M(+7.3%)
-$24.11 M(-734.5%)
-$66.42 M(+19.6%)
Sep 2023
-
$3.80 M(-121.1%)
-$55.51 M(-31.6%)
Jun 2023
-
-$18.04 M(-35.7%)
-$81.19 M(+1.9%)
Mar 2023
-
-$28.07 M(+112.6%)
-$79.67 M(+28.7%)
Dec 2022
-$61.91 M(-2538.2%)
-$13.20 M(-39.7%)
-$61.91 M(+23.1%)
Sep 2022
-
-$21.88 M(+32.5%)
-$50.30 M(+114.0%)
Jun 2022
-
-$16.52 M(+60.3%)
-$23.51 M(+78.0%)
Mar 2022
-
-$10.30 M(+543.9%)
-$13.21 M(-620.0%)
Dec 2021
$2.54 M(-101.7%)
-$1.60 M(-132.6%)
$2.54 M(-103.2%)
Sep 2021
-
$4.91 M(-179.0%)
-$79.08 M(-15.5%)
Jun 2021
-
-$6.21 M(-214.1%)
-$93.55 M(-23.0%)
Mar 2021
-
$5.45 M(-106.5%)
-$121.50 M(-16.8%)
Dec 2020
-$146.09 M(+87.9%)
-$83.22 M(+770.1%)
-$146.09 M(+69.1%)
Sep 2020
-
-$9.56 M(-72.0%)
-$86.41 M(-7.7%)
Jun 2020
-
-$34.17 M(+78.5%)
-$93.64 M(+14.8%)
Mar 2020
-
-$19.14 M(-18.7%)
-$81.56 M(+4.9%)
Dec 2019
-$77.74 M(+38.9%)
-$23.54 M(+40.2%)
-$77.74 M(+10.0%)
Sep 2019
-
-$16.79 M(-24.0%)
-$70.65 M(+4.1%)
Jun 2019
-
-$22.09 M(+44.1%)
-$67.87 M(+15.9%)
Mar 2019
-
-$15.33 M(-6.8%)
-$58.57 M(+4.7%)
Dec 2018
-$55.95 M
-$16.44 M(+17.3%)
-$55.95 M(+8.4%)
DateAnnualQuarterlyTTM
Sep 2018
-
-$14.01 M(+9.6%)
-$51.59 M(-1.1%)
Jun 2018
-
-$12.78 M(+0.5%)
-$52.17 M(-8.9%)
Mar 2018
-
-$12.71 M(+5.2%)
-$57.26 M(-4.4%)
Dec 2017
-$59.87 M(+42.1%)
-$12.08 M(-17.2%)
-$59.87 M(-0.1%)
Sep 2017
-
-$14.59 M(-18.3%)
-$59.94 M(+10.4%)
Jun 2017
-
-$17.87 M(+16.7%)
-$54.30 M(+14.9%)
Mar 2017
-
-$15.32 M(+26.1%)
-$47.24 M(+12.1%)
Dec 2016
-$42.14 M(+13.1%)
-$12.15 M(+35.7%)
-$42.14 M(+5.3%)
Sep 2016
-
-$8.95 M(-17.2%)
-$40.02 M(-4.7%)
Jun 2016
-
-$10.82 M(+5.9%)
-$41.99 M(+3.5%)
Mar 2016
-
-$10.22 M(+1.9%)
-$40.59 M(+8.9%)
Dec 2015
-$37.27 M(+38.1%)
-$10.03 M(-8.2%)
-$37.27 M(+7.6%)
Sep 2015
-
-$10.92 M(+16.0%)
-$34.62 M(+13.7%)
Jun 2015
-
-$9.42 M(+36.5%)
-$30.44 M(+12.7%)
Mar 2015
-
-$6.90 M(-6.5%)
-$27.01 M(+0.1%)
Dec 2014
-$26.98 M(+116.3%)
-$7.38 M(+9.5%)
-$26.98 M(+17.9%)
Sep 2014
-
-$6.74 M(+12.7%)
-$22.89 M(+17.5%)
Jun 2014
-
-$5.98 M(-12.9%)
-$19.48 M(+18.9%)
Mar 2014
-
-$6.87 M(+108.9%)
-$16.39 M(+31.4%)
Dec 2013
-$12.47 M(-6.3%)
-$3.29 M(-1.4%)
-$12.47 M(+35.8%)
Sep 2013
-
-$3.34 M(+15.5%)
-$9.18 M(+57.1%)
Jun 2013
-
-$2.89 M(-2.3%)
-$5.85 M(+97.7%)
Mar 2013
-
-$2.96 M
-$2.96 M
Dec 2012
-$13.31 M
-
-

FAQ

  • What is Ocular Therapeutix annual EBITDA?
  • What is the all time high annual EBITDA for Ocular Therapeutix?
  • What is Ocular Therapeutix annual EBITDA year-on-year change?
  • What is Ocular Therapeutix quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Ocular Therapeutix?
  • What is Ocular Therapeutix quarterly EBITDA year-on-year change?
  • What is Ocular Therapeutix TTM EBITDA?
  • What is the all time high TTM EBITDA for Ocular Therapeutix?
  • What is Ocular Therapeutix TTM EBITDA year-on-year change?

What is Ocular Therapeutix annual EBITDA?

The current annual EBITDA of OCUL is -$66.42 M

What is the all time high annual EBITDA for Ocular Therapeutix?

Ocular Therapeutix all-time high annual EBITDA is $2.54 M

What is Ocular Therapeutix annual EBITDA year-on-year change?

Over the past year, OCUL annual EBITDA has changed by -$4.51 M (-7.28%)

What is Ocular Therapeutix quarterly EBITDA?

The current quarterly EBITDA of OCUL is -$32.31 M

What is the all time high quarterly EBITDA for Ocular Therapeutix?

Ocular Therapeutix all-time high quarterly EBITDA is $5.45 M

What is Ocular Therapeutix quarterly EBITDA year-on-year change?

Over the past year, OCUL quarterly EBITDA has changed by -$36.11 M (-950.26%)

What is Ocular Therapeutix TTM EBITDA?

The current TTM EBITDA of OCUL is -$155.92 M

What is the all time high TTM EBITDA for Ocular Therapeutix?

Ocular Therapeutix all-time high TTM EBITDA is $2.54 M

What is Ocular Therapeutix TTM EBITDA year-on-year change?

Over the past year, OCUL TTM EBITDA has changed by -$100.41 M (-180.89%)